Tigecycline is accustomed intravenously and has action adjoin a array of Gram-positive and Gram-negative bacterial pathogens, abounding of which are aggressive to absolute antibiotics. Tigecycline auspiciously completed appearance III trials in which it was at atomic according to intravenous vancomycin and aztreonam to amusement complicated derma and derma anatomy infections (cSSSI), and to intravenous imipenem and cilastatin to amusement complicated intra-abdominal infections (cIAI). Tigecycline is alive adjoin abounding Gram-positive bacteria, Gram-negative bacilli and anaerobes – including action adjoin methicillin-resistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, Haemophilus influenzae, and Neisseria gonorrhoeae (with MIC ethics appear at 2 µg/mL) and multi-drug aggressive strains of Acinetobacter baumannii. It has no action adjoin Pseudomonas spp. or Proteus spp. The biologic is licenced for the analysis of derma and bendable tissue infections as able-bodied as intra-abdominal infections.